Eli Lilly Canada Inc.
3650 Danforth Avenue
12 articles with Eli Lilly Canada Inc.
New anti-CGRP treatment for the prevention of migraine in adults with at least 4 migraine days per month
Eli Lilly Canada Inc. (Lilly Canada) is pleased to announce the availability of VERZENIO™ (abemaciclib). VERZENIO is indicated for the treatment of estrogen and/or progesterone hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) metastatic breast cancer (
With availability of Olumiant (baricitinib), Lilly brings new oral treatment option for Canadians living with rheumatoid arthritis
"You would never know by looking at me," says Angela Vance, a Lilly employee, "that I have rheumatoid arthritis (RA)."
Eli Lilly Canada and Women in Biz Network Partner to Shift Perceptions of Rheumatoid Arthritis in the Workplace
A series of local events and career progression resources to support women living and working with a chronic disease
The approval of Taltz is based on the Phase 3 clinical trials that demonstrated efficacy on both joints and skin symptomsi
Eli Lilly Canada Inc. (Lilly) is proud to announce that Humalog® [insulin lispro injection 100 units/mL] Junior KwikPen® is approved by Health Canada and now available to Canadians with diabetes.
Eli Lilly Canada Inc. Release: Health Canada's Approval Of Taltz (Ixekizumab) Brings Targeted Therapy To Canadians Living With Moderate-To-Severe Plaque Psoriasis
Boehringer Ingelheim And Eli Lilly Canada Inc. Release: Health Canada Approves JARDIANCE (empagliflozin) Tablets For Adults With Type 2 Diabetes
Boehringer Ingelheim Corporation and Eli Lilly Canada Inc. Present New linagliptin Data at American Diabetes Association's 72nd Scientific Sessions®
FDA Delays Approval of Amylin Pharmaceuticals, Inc., Eli Lilly Canada Inc. (JOBS) Diabetes Drug; FDA Requests Finalization of Product Labeling